Search Results for "Adis International Langhorne Pa"
Original Source: Adis International - USA
Adis provides total communications solutions for the pharmaceutical and related industries. In addition to producing a range of specialized drug information products, Adis works closely with you to provide strategic and tactical support for all your healthcare communications needs.
Matching Channels
College Hill - international business communications consultancy
College Hill is a growing international business communications consultancy with offices in Europe, China, India, South Africa and the United States. College Hill's wide range of complementar...
Able to take advantage of a €2 European funding stimulus in 2009, the Czech Republic is one of Europe's top 5 centers for biotechnology companies. In just over decade, the Czech Republic ha...
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in term...
GMO Crops - news, views, reports
Transgenic plants have been engineered to possess several desirable traits, such as resistance to pests, herbicides, or harsh environmental conditions, improved product shelf life, and increased nut...
The Top 10 Medical Device Companies
Medical devices are crucial to the process of diagnosis and treatment in modern medicine. Sales in this field reach billions of dollar a year, with Johnson & Johnson making $30 billion alone in...
Matching News
Langhorne, PA - St. Mary Emergency Department Unveils New Entrance
St. Mary Medical Center, Langhorne, PA, recently completed phase II of an emergency department expansion. Phase II introduced a new emergency department entrance and reception area as well as a new...
Langhorne, PA - St. Mary Offers Transcatheter Aortic Valve Replacement
St. Mary Medical Center, Langhorne, PA, recently began offering transcatheter aortic valve replacement for patients with heart disease. A minimally invasive procedure, transcatheter aortic valve repla...
New hope for survivors of stroke and traumatic brain injury
(Springer) A new ground-breaking study about to be published in the Adis journal CNS Drugs provides clinical evidence that, for the first time, chronic neurological dysfunction from stroke or traumati...
Substandard, non-approved drugs put patients at risk
(Springer Science+Business Media ) The recent outbreak of meningitis in the US -- and the subsequent deaths of 15 individuals -- has renewed scrutiny on the contemporary practice of pharmacy compoundi...
Physicians urged to think twice before they prescribe compounded drugs
The recent outbreak of meningitis in the US-and the subsequent deaths of 15 individuals-has renewed scrutiny on the contemporary practice of pharmacy compounding. The risks to patients, and associated...
Single dose of etanercept can improve chronic neurological dysfunction from stroke or TBI
A new ground-breaking study about to be published in the Adis journal CNS Drugs provides clinical evidence that, for the first time, chronic neurological dysfunction from stroke or traumatic brain inj...
Cypress, CA, Costa Mesa, CA, Langhorne, PA, Garden City, NY (PRWEB) January 02, 2013 WCCT Global , a Full Service Contract Research Organization (CRO) supporting Phase I - IV biopharmaceutical an...
Woods Awarded $1 Million Grant
LANGHORNE, Pa., May 6, 2013 /PRNewswire-USNewswire/ -- Woods, celebrating 100 years as a leading advocacy and service organization for people with exceptional challenges and disabilities and comp...
Matching PubMed Articles
Linaclotide: first global approval.
Linaclotide is a once-daily, orally administered, first-in-class agonist of guanylate cyclase-C that is minimally absorbed. It is being developed to treat gastrointestinal disorders by Ironwood Pharma...
Once-Daily Memantine : A Guide to its Use in Moderate to Severe Alzheimer's Disease in the EU.
In the EU, once-daily memantine 20 mg (Axura(®), Ebixa(®)) is an option for the management of patients with moderate to severe Alzheimer's disease (AD). In pooled clinical trials and studies in the...
Lixisenatide: First Global Approval.
The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenati...
Pomalidomide: First Global Approval.
Pomalidomide (Pomalyst(®)) is a small molecule analogue of thalidomide under development with Celgene Corporation for the oral treatment of haematological and connective tissue diseases. Pomalidomide...
